PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
PHXM was delisted on the 8th of March, 2024.
6 hedge funds and large institutions have $1.65M invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
20% more funds holding
Funds holding: 5 → 6 (+1)
5.96% less ownership
Funds ownership: 10.81% → 4.85% (-6%)
72% less capital invested
Capital invested by funds: $5.97M → $1.65M (-$4.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Personalized Indexing Management
Oakland,
California
|
+$118K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$44.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$10.8K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$5.23K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$210 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$3.4M |
| 2 |
Jane Street
New York
|
-$93K |
PHXM Hedge Fund Activity: Q2 2022 in Review
6 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q2 2022, worth a combined $1.65M — down 72% from $5.97M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PHXM positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Personalized Indexing Management, opening a new position worth an estimated $118K. The largest seller was Armistice Capital, exiting entirely with an estimated $3.4M sold.
- 6 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q2 2022, up from 5 in Q1 2022.
- Funds reported $1.65M of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q2 2022, down 72% quarter-over-quarter.
- 3 funds opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q2 2022 and 2 closed out, a net change of +1 holder.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares buyer in Q2 2022 was Vanguard Personalized Indexing Management, an estimated $118K added.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares seller in Q2 2022 was Armistice Capital, an estimated $3.4M sold.
Based on aggregated 13F filings for Q2 2022.